CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 77 enrolled
Drug / intervention
EYP-1901 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05383209
NCT05383209Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

EyePoint Pharmaceuticals, Inc.·interventional·Posted May 20, 2022·Updated Aug 15, 2025

In Brief

A Phase 2 clinical trial evaluating EYP-1901 and Sham IVT for Nonproliferative Diabetic Retinopathy. Completed, enrolled 77 participants across 36 sites.

Detailed Summary

A prospective, randomized, double-masked study that evaluated the ocular efficacy and safety of two doses of the EYP-1901 intravitreal (IVT) insert compared to sham.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonproliferative Diabetic Retinopathy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMay 20, 2022
Enrollment StartSep 28, 2022
Primary CompletionFeb 12, 2024
Study CompletionMay 6, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.1 years ago

Interventions

EYP-1901drug

EYP-1901 will be administered to the study eye by a single injection through the pars plana using a pre-loaded applicator with a 22-gauge needle. Each EYP-1901 IVT insert has been designed to deliver vorolanib into the vitreous humor for approximately 6 to 9 months.

Sham IVTother

Sham injections will be used to maintain masking of investigational EYP-1901 therapy for study subjects.